$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024021069 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$109.3M	$92.76M
YoY Change	32.54%	34.87%
Cost Of Revenue	$1.699M	$1.265M
YoY Change	78.84%	34.86%
Gross Profit	$107.6M	$91.50M
YoY Change	32.0%	34.87%
Gross Profit Margin	98.45%	98.64%
Selling, General & Admin	$61.21M	$59.36M
YoY Change	20.03%	24.02%
% of Gross Profit	56.87%	64.88%
Research & Development	$37.62M	$46.49M
YoY Change	-26.58%	-3.92%
% of Gross Profit	34.95%	50.81%
Depreciation & Amortization	$320.0K	$306.0K
YoY Change	-21.38%	-24.44%
% of Gross Profit	0.3%	0.33%
Operating Expenses	$98.84M	$105.9M
YoY Change	-3.33%	9.98%
Operating Profit	$8.761M	-$14.49M
YoY Change	-142.32%	-49.01%
Interest Expense	$24.73M	$24.51M
YoY Change	-199.47%	-201.07%
% of Operating Profit	282.31%
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.50M	-$35.01M
YoY Change	-83.24%	-33.51%
Income Tax	$172.0K	$365.0K
% Of Pretax Income
Net Earnings	-$12.67M	-$35.38M
YoY Change	-83.17%	-33.66%
Net Earnings / Revenue	-11.59%	-38.14%
Basic Earnings Per Share	-$0.06	-$0.17
Diluted Earnings Per Share	-$0.06	-$0.17
COMMON SHARES
Basic Shares Outstanding	206.4M shares	206.1M shares
Diluted Shares Outstanding	206.4M shares	206.1M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$272.0M	$336.6M
YoY Change	-33.76%	-15.47%
Cash & Equivalents	$78.41M	$84.33M
Short-Term Investments	$193.6M	$252.2M
Other Short-Term Assets	$18.22M	$20.18M
YoY Change	16.16%	21.41%
Inventory	$4.450M	$29.78M
Prepaid Expenses
Receivables	$68.76M	$60.59M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$363.5M	$447.1M
YoY Change	-28.88%	-8.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.663M	$7.831M
YoY Change	-9.18%	-6.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$64.32M
YoY Change	1766.97%
Other Assets	$12.46M	$12.96M
YoY Change	79.34%	83.95%
Total Long-Term Assets	$109.0M	$20.79M
YoY Change	478.69%	10.28%
TOTAL ASSETS
Total Short-Term Assets	$363.5M	$447.1M
Total Long-Term Assets	$109.0M	$20.79M
Total Assets	$472.4M	$467.9M
YoY Change	-10.84%	-8.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.786M	$11.91M
YoY Change	-43.94%	90.44%
Accrued Expenses	$89.60M	$79.25M
YoY Change	18.99%	5.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$30.66M	$27.66M
YoY Change
Total Short-Term Liabilities	$129.1M	$119.9M
YoY Change	38.04%	40.82%
LONG-TERM LIABILITIES
Long-Term Debt	$313.8M	$308.5M
YoY Change	7.04%	32.67%
Other Long-Term Liabilities	$8.362M	$8.596M
YoY Change	44.1%	44.86%
Total Long-Term Liabilities	$313.8M	$308.5M
YoY Change	7.04%	32.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$129.1M	$119.9M
Total Long-Term Liabilities	$313.8M	$308.5M
Total Liabilities	$442.9M	$428.4M
YoY Change	14.54%	34.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.729B	-$1.717B
YoY Change	9.22%	13.83%
Common Stock	$2.066M	$2.063M
YoY Change	9.02%	9.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$475.6M	-$476.2M
YoY Change
Total Liabilities & Shareholders Equity	$472.4M	$467.9M
YoY Change	-10.84%	-8.21%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$12.67M	-$35.38M
YoY Change	-83.17%	-33.66%
Depreciation, Depletion And Amortization	$320.0K	$306.0K
YoY Change	-21.38%	-24.44%
Cash From Operating Activities	-$1.368M	-$53.68M
YoY Change	-92.73%	12.99%
INVESTING ACTIVITIES
Capital Expenditures	$155.0K	$235.0K
YoY Change	-66.81%	46.88%
Acquisitions
YoY Change
Other Investing Activities	-$2.294M	$28.99M
YoY Change	-87.65%	-127.11%
Cash From Investing Activities	-$2.449M	$28.76M
YoY Change	-87.13%	-126.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.966M	-$1.048M
YoY Change	-106.7%	-120.64%
NET CHANGE
Cash From Operating Activities	-1.368M	-$53.68M
Cash From Investing Activities	-2.449M	$28.76M
Cash From Financing Activities	-1.966M	-$1.048M
Net Change In Cash	-5.783M	-$26.32M
YoY Change	-31.91%	-82.41%
FREE CASH FLOW
Cash From Operating Activities	-$1.368M	-$53.68M
Capital Expenditures	$155.0K	$235.0K
Free Cash Flow	-$1.523M	-$53.92M
YoY Change	-92.1%	13.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7831000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7910000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	119921000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	149988000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8596000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8390000	usd
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	206347000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	206347000	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	92761000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	68778000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1265000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	931000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesCurrent
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesCurrent
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12961000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13084000	usd
CY2024Q1	us-gaap	Assets Assets	467892000	usd
CY2023Q4	us-gaap	Assets Assets	516960000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11910000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	20893000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	79249000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	102882000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1098000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1642000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1590000	usd
CY2024Q1	bcrx	Royalty Financing Liabilities Current RoyaltyFinancingLiabilitiesCurrent	26022000	usd
CY2023Q4	bcrx	Royalty Financing Liabilities Current RoyaltyFinancingLiabilitiesCurrent	23565000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2506000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2845000	usd
CY2024Q1	bcrx	Royalty Financing Liabilities Noncurrent RoyaltyFinancingLiabilitiesNoncurrent	504552000	usd
CY2023Q4	bcrx	Royalty Financing Liabilities Noncurrent RoyaltyFinancingLiabilitiesNoncurrent	508034000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	308484000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	303231000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	205771000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	205771000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2063000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2058000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1237537000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1222236000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	771000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1337000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1716538000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1681159000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-476167000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-455528000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	467892000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	516960000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46493000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48388000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	59364000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	47867000	usd
CY2024Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	127000	usd
CY2023Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	7000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	107249000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	97193000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14488000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28415000	usd
CY2024Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	4031000	usd
CY2023Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	3378000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	24506000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	27396000	usd
CY2024Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-51000	usd
CY2023Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-229000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35014000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52662000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	365000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	671000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35379000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53333000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-253000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	59000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-313000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	500000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35945000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52774000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	206064000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	206064000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188509000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188509000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35379000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53333000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	306000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	405000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	236000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13652000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14007000	usd
CY2024Q1	bcrx	Non Cash Interest Expense On Royalty Financing Liabilities And Secured Term Loan And Amortization Of Debt Issuance Costs NonCashInterestExpenseOnRoyaltyFinancingLiabilitiesAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts	19440000	usd
CY2023Q1	bcrx	Non Cash Interest Expense On Royalty Financing Liabilities And Secured Term Loan And Amortization Of Debt Issuance Costs NonCashInterestExpenseOnRoyaltyFinancingLiabilitiesAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts	20216000	usd
CY2024Q1	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-3181000	usd
CY2023Q1	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-1385000	usd
CY2024Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3839000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2019000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1220000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-131000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1106000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2547000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-44569000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27226000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-35000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53684000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47512000	usd
CY2024Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	235000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	160000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	88009000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	148637000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	117000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	41688000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28756000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107109000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1681000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5077000	usd
CY2024Q1	bcrx	Proceeds From Issuance Of Common Stock Issued For Services ProceedsFromIssuanceOfCommonStockIssuedForServices	11000	usd
CY2023Q1	bcrx	Proceeds From Issuance Of Common Stock Issued For Services ProceedsFromIssuanceOfCommonStockIssuedForServices	0	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2350000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	390000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1048000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5077000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-340000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-96000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26316000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-149640000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	306239000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86131000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	156599000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	4987000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	7142000	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	186000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	142000	usd
CY2024Q1	bcrx	Withholding Taxes Accrued WithholdingTaxesAccrued	1846000	usd
CY2023Q1	bcrx	Withholding Taxes Accrued WithholdingTaxesAccrued	2128000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-455528000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35379000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-566000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	552000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	38000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1129000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13652000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-476167000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-294597000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53333000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	559000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3502000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1575000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14007000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company’s condensed consolidated financial statements have been made relative to the calculation of net product sales, the ORLADEYO and Factor D inhibitors royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company’s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	92761000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	68778000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1798000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1804000	usd
CY2024Q1	bcrx	Long Term Investment Maturity Minimum LongTermInvestmentMaturityMinimum	P12M
CY2024Q1	bcrx	Royalty Financing Liabilities RoyaltyFinancingLiabilities	530574000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	1418000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1850000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45704000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	55535000	shares
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	2700000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	2293000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1766000	usd
CY2023Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
CY2024Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	92761000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	68778000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	252221000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	14	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	171437000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	252405000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	51000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	236000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	252221000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	278131000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	135000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	150000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	72000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	252221000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	278344000	usd
CY2024Q1	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	0	usd
CY2023Q4	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	252221000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1589000	usd
CY2024Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	3578000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	2296000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	7526000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6449000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	16864000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	17591000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6990000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6242000	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	31380000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	30282000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1599000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1599000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	29781000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	28683000	usd
CY2023Q4	bcrx	Royalty Financing Liabilities RoyaltyFinancingLiabilities	531599000	usd
CY2024Q1	bcrx	Non Cash Interest Expense On Royalty Financing Liabilities NonCashInterestExpenseOnRoyaltyFinancingLiabilities	14187000	usd
CY2024Q1	bcrx	Royalty Revenues Paid And Payable RoyaltyRevenuesPaidAndPayable	-15212000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	590000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	433000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	407000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	256000	usd
CY2024Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	77000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	38000	usd
CY2024Q1	bcrx	Financing Lease Expense FinancingLeaseExpense	484000	usd
CY2023Q1	bcrx	Financing Lease Expense FinancingLeaseExpense	294000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y8M12D
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1089
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1088
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0759
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0746
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8864000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8682000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1098000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8596000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8390000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9694000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9448000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4018000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4322000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1642000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1590000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2506000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2845000	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	4148000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4435000	usd
CY2024Q1	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	5120000	usd
CY2023Q4	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	4794000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1661000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	933000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1584000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	459000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1416000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	31000	usd
CY2024Q1	bcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	7997000	usd
CY2024Q1	bcrx	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16097000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4607000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6403000	usd
CY2024Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	459000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9694000	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	4148000	usd
CY2024Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	77000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	282000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	525000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	423000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	390000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	156000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	95000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	103000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	610000	usd
CY2024Q1	bcrx	Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities	365000	usd
CY2023Q1	bcrx	Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities	0	usd
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	57438000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	58020000	shares
CY2024Q1	bcrx	Share Based Payment Arrangement Number Of Plans ShareBasedPaymentArrangementNumberOfPlans	3	plan
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13652000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14007000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	251000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	176000	shares
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	3380000	usd
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	1264000	usd
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	3168000	usd
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	1476000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-021069-index-headers.html	Edgar Link	pending
0001628280-24-021069-index.html	Edgar Link	pending
0001628280-24-021069.txt	Edgar Link	pending
0001628280-24-021069-xbrl.zip	Edgar Link	pending
bcrx-20240331.htm	Edgar Link	pending
bcrx-20240331.xsd	Edgar Link	pending
bcrx-20240331xexx311.htm	Edgar Link	pending
bcrx-20240331xexx312.htm	Edgar Link	pending
bcrx-20240331xexx321.htm	Edgar Link	pending
bcrx-20240331xexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
bcrx-20240331_htm.xml	Edgar Link	completed
bcrx-20240331_lab.xml	Edgar Link	unprocessable
bcrx-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bcrx-20240331_def.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bcrx-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2024 Q2 Form 10-Q Financial Statement

#000162828024021069 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2024 Q2 Form 10-Q Financial Statement

#000162828024021069 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx